Evidence map›Paper›PMID 35836204›Full record

ArticleBMC cancer2022

Update of a prognostic survival model in head and neck squamous cell carcinoma patients treated with immune checkpoint inhibitors using an expansion cohort.

Majd Issa, Brett G Klamer, Nikol Mladkova, Georgios I Laliotis, Vidhya Karivedu, Priyanka Bhateja, Chase Byington, Khaled Dibs, Xueliang Pan, Arnab Chakravarti and 9 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.7field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 3 institutions in 1 country.

Majd IssaDepartment of Internal Medicine, Division of Medical Oncology, The Ohio State University Wexner Medical Center, Columbus, OH, 43210, USA. majd.issa@osumc.edu.
Brett G KlamerCenter for Biostatistics, Department of Biomedical Informatics, The Ohio State University, Columbus, OH, 43210, USA.
Nikol MladkovaDivision of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, OH, 43210, USA.
Georgios I LaliotisSidney Kimmel Comprehensive Cancer Center and Department of Oncology, Johns Hopkins University, Baltimore, MD, 21231, USA.
Vidhya KariveduDepartment of Internal Medicine, Division of Medical Oncology, The Ohio State University Wexner Medical Center, Columbus, OH, 43210, USA.
Priyanka BhatejaDepartment of Internal Medicine, Division of Medical Oncology, The Ohio State University Wexner Medical Center, Columbus, OH, 43210, USA.
Chase ByingtonDepartment of Internal Medicine, Division of Medical Oncology, The Ohio State University Wexner Medical Center, Columbus, OH, 43210, USA.
Khaled DibsDivision of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, OH, 43210, USA.
Xueliang PanCenter for Biostatistics, Department of Biomedical Informatics, The Ohio State University, Columbus, OH, 43210, USA.
Arnab ChakravartiDivision of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, OH, 43210, USA.
John GreculaDivision of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, OH, 43210, USA.
Sachin R JhawarDivision of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, OH, 43210, USA.
Darrion MitchellDivision of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, OH, 43210, USA.
Sujith BaligaDivision of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, OH, 43210, USA.
Matthew OldDepartment of Otolaryngology - Head and Neck Surgery, The Ohio State University Wexner Medical Center, Columbus, OH, 43210, USA.
Ricardo L CarrauDepartment of Otolaryngology - Head and Neck Surgery, The Ohio State University Wexner Medical Center, Columbus, OH, 43210, USA.
James W RoccoDepartment of Otolaryngology - Head and Neck Surgery, The Ohio State University Wexner Medical Center, Columbus, OH, 43210, USA.
Dukagjin M Blakaj *Division of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, OH, 43210, USA.
Marcelo Bonomi *Department of Internal Medicine, Division of Medical Oncology, The Ohio State University Wexner Medical Center, Columbus, OH, 43210, USA.
The Ohio State University Wexner Medical Center · USThe Ohio State University · USSidney Kimmel Comprehensive Cancer Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundImmune checkpoint inhibitors (ICI) treatment in recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) offers new therapeutic venues. We have previously developed a predictive survival model in this patient population based on clinical parameters, and the purpose of this study was to expand the study cohort and internally validate the model.

methodsA single institutional retrospective analysis of R/M HNSCC patients treated with ICI. Clinical parameters collected included p-16 status, hemoglobin (Hb), albumin (Alb), lactate dehydrogenase (LDH), neutrophil, lymphocyte and platelet counts. Cox proportional hazard regression was used to assess the impact of patient characteristics and clinical variables on survival. A nomogram was created using the rms package to generate individualized survival prediction.

results201 patients were included, 47 females (23%), 154 males (77%). Median age was 61 years (IQR: 55-68). P-16 negative (66%). Median OS was 12 months (95% CI: 9.4, 14.9). Updated OS model included age, sex, absolute neutrophil count, absolute lymphocyte count, albumin, hemoglobin, LDH, and p-16 status. We stratified patients into three risk groups based on this model at the 0.33 and 0.66 quantiles. Median OS in the optimal risk group reached 23.7 months (CI: 18.5, NR), 13.8 months (CI: 11.1, 20.3) in the average risk group, and 2.3 months (CI: 1.7, 4.4) in the high-risk group. Following internal validation, the discriminatory power of the model reached a c-index of 0.72 and calibration slope of 0.79.

conclusionsOur updated nomogram could assist in the precise selection of patients for which ICI could be beneficial and cost-effective.

Indexed as

Head and Neck NeoplasmsImmune Checkpoint InhibitorsAlbuminsFemaleHemoglobinsHumansMaleMiddle AgedNeoplasm Recurrence, LocalPrognosisRetrospective StudiesSquamous Cell Carcinoma of Head and NeckAlbuminsHemoglobinsImmune Checkpoint InhibitorsHead and neck cancerHead and neck squamous cell carcinomaImmune checkpoint inhibitorsImmunotherpaySurvival in head and neck cancer

Identifiers

PMID35836204
PMCPMC9284772
OpenAlexW4285494377

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.